BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The 15 Most Powerful Forerunners in Business - 2Manual for Notorious Fragrances: Immortal Aromas
- 3More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- 4Don't miss these five impressive spots in Bangkok
- 5Figuring out Significant Regulations and Guidelines for Organizations
- Watch comet C/2026 A1 plunge toward the sun online this week
- Find Your Internal Culinary expert: Cooking Strategies and Recipes
- Building a Maintainable Closet: Individual Excursions in Moral Style
- Orbán orders stop to gas deliveries to Ukraine via Hungary from July
- Space Condos to Lift Your Metropolitan Living
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- Study reveals links between global food systems, obesity, and climate change
- Instructions to Discuss Successfully with Your Auto Collision Lawyer
